The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a more substantial reduction in body size and benefit metabolic health, par